"As we move through 2026, next-generation cell therapy is shifting from promise to proof." (CEO David Chang) "In this 24-patient analysis, cema-cel achieved a 58.3% MRD clearance rate compared with 16 ...
Orthopedic-driven ASCs (facilities with greater than 50 percent of their case volume in orthopedics) commit an average of 71.3 percent of their net revenue to operating expenses, according to VMG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results